Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00710736 · ClinicalTrials.gov registry record · Phase 1
A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
A Phase 1 study, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00710736 is a Phase 1 study that has completed, run by Array Biopharma, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 29 participants.
The verdict
NCT00710736, a Phase 1 study, has completed, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and capecitabine. Patients will receive increasing doses of study drug in combination with capecitabine in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 30 patients from the US and Canada will be enrolled in this study.
Interventions
- DRUG ARRY-334543, EGFR/ErbB2 inhibitor; oral
- DRUG Capecitabine, 5-fluorouracil prodrug; oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00710736
The ClinicalTrials.gov registry entry for NCT00710736 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ARRY-334543, EGFR/ErbB2 inhibitor; oral is the first listed.
NCT00710736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00710736 about?
NCT00710736 is a clinical study titled "A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer". This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and capecitabine. Patients will receive increasing doses of study drug in combination with capecitabine in order to achieve the highest dose of study drug possible ...
What is the current status of trial NCT00710736?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2008-06. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00710736?
The interventions under investigation include: ARRY-334543, EGFR/ErbB2 inhibitor; oral (DRUG), Capecitabine, 5-fluorouracil prodrug; oral (DRUG).
Who is sponsoring clinical trial NCT00710736?
This trial is sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.